GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Earnings per Share (Diluted)

Shanghai Junshi Biosciences Co (HKSE:01877) Earnings per Share (Diluted) : HK$-1.27 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Earnings per Share (Diluted)?

Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was HK$-0.32. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.27.

Shanghai Junshi Biosciences Co's EPS (Basic) for the three months ended in Mar. 2024 was HK$-0.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.27.

Shanghai Junshi Biosciences Co's EPS without NRI for the three months ended in Mar. 2024 was HK$-0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.23.

During the past 3 years, the average EPS without NRIGrowth Rate was -1.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.30% per year.

During the past 8 years, Shanghai Junshi Biosciences Co's highest 3-Year average EPS without NRI Growth Rate was 5.10% per year. The lowest was -73.60% per year. And the median was -39.70% per year.


Shanghai Junshi Biosciences Co Earnings per Share (Diluted) Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Earnings per Share (Diluted) Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.06 -2.40 -0.98 -2.90 -2.54

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.50 -0.45 - -0.32

Competitive Comparison of Shanghai Junshi Biosciences Co's Earnings per Share (Diluted)

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's PE Ratio falls into.



Shanghai Junshi Biosciences Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Shanghai Junshi Biosciences Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2495.592-0)/985.302
=-2.53

Shanghai Junshi Biosciences Co's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-307.455-0)/975.962
=-0.32

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Shanghai Junshi Biosciences Co  (HKSE:01877) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Shanghai Junshi Biosciences Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Executives
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd 2101 Beneficial owner
Jovial Champion Investments Limited 2201 Interest of corporation controlled by you
Gong Ruilin 2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited 2201 Interest of corporation controlled by you
Lvc Holdings Limited 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lvc Innovate Limited 2201 Interest of corporation controlled by you
Lin Lijun 2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp 2101 Beneficial owner
Lvc Renaissance Limited 2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited 2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines